Skip to Content Skip to Content

Perelman School of Medicine

Visit the School's Site
Reset All Filters
2719 Results
Treatment in a FLASH
St. Bernard dog with three legs sits outside near a pile of firewood

Milo, a 4-year-old Saint Bernard, participated in the FLASH trial. “I think that we greatly underestimate the excitement of pet owners to be involved in research and to be able to contribute to a project like this,” says Penn Vet surgeon Jennifer Huck, who is co-leading the effort with Penn Medicine’s Keith Cengel, a radiation oncologist. (Image: Courtesy of the Gordon family)

Treatment in a FLASH

A clinical trial in dogs with cancer, co-led by the Perelman School of Medicine and the School of Veterinary Medicine, is testing the feasibility, safety, and effectiveness of delivering a full dose of radiation therapy in a split second.

Katherine Unger Baillie

Meet the biology major who brought an Iowa caucus to Philadelphia
A group of people talking and laughing in a cluster, with a video camera being held in the top left corner.

Junior Jessica Anderson (center) of Titonka, Iowa, organized an Iowa satellite caucus in Philadelphia, one of more than 90 that took place worldwide. Fourteen people, mostly area college students, participated. 

Meet the biology major who brought an Iowa caucus to Philadelphia

Junior Jessica Anderson organized the satellite event because she wanted to participate in the political process. Politics aside, she’s aiming for a career that combines research and patient care.

Michele W. Berger

Defect driving resistance to CAR T therapy identified
A CAR T cell interacting with a cancer cell

A CAR T cell interacting with a cancer cell.

Defect driving resistance to CAR T therapy identified

A new study identifies the mechanism that prevents cell death, and can guide future immunotherapy strategies in patients whose blood cancers are resistant to CAR T therapy.

Penn Today Staff

Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy
An artist’s illustration of nanoparticles transporting mRNA into a T cell, allowing the latter to express surface receptors that recognize cancer cells.

An artist’s illustration of nanoparticles transporting mRNA into a T cell (blue), allowing the latter to express surface receptors that recognize cancer cells (red). (Image: Ryan Allen, Second Bay Studios)

Penn nanoparticles are less toxic to T cells engineered for cancer immunotherapy

By using messenger RNA across the T cell’s membrane via a nanoparticle instead of a DNA-rewriting virus on extracted T cells, CAR T treatments could have fewer side effects.

Penn Today Staff

New vaccines to protect infants from infections
Infant lying on their back with a doctor and nurse standing above with a vaccine injection

New vaccines to protect infants from infections

A new Penn Medicine study puts researchers within closer reach of vaccines that can protect infants against infections by overcoming a mother’s antibodies.

Penn Today Staff